Traverse Biotech

Traverse Biotech is a preclinical-stage biotech leveraging a unique partnership model to develop novel immunotherapies. The company identifies and licenses promising, clinically validated therapeutic platforms from international partners, sharing development risk and expertise to accelerate programs from preclinical through proof-of-concept. Its lead asset is a CD3 x ROR2 DuoBody bispecific antibody for oncology, with a broader pipeline targeting innate immunity in oncology and aging. The experienced leadership team combines deep expertise in immunology, drug development, and business strategy to execute this capital-efficient model.

Business model focused on in-licensing and co-developing clinically validated immunotherapy platforms (e.g., DuoBody bispecific antibody technology) via risk-sharing partnerships.

Traverse competes in the crowded bispecific T-cell engager space dominated by large pharma, though its focus on the novel ROR2 target may offer differentiation. Its partnership-based model also competes with other biotech accelerators and venture studios for high-quality external assets.